This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chau, A. S.
Right arrow Articles by Mann, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chau, A. S.
Right arrow Articles by Mann, P. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2006, p. 3917-3919, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00747-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Molecular Basis for Enhanced Activity of Posaconazole against Absidia corymbifera and Rhizopus oryzae{triangledown}

Andrew S. Chau, Guodong Chen, Paul M. McNicholas,* and Paul A. Mann

Schering-Plough Research Institute, 2015 Galloping Hill Road, 4700, Kenilworth, New Jersey 07033

Received 19 June 2006/ Returned for modification 15 July 2006/ Accepted 30 August 2006

Posaconazole and itraconazole were more potent inhibitors of ergosterol synthesis, in both intact cells and cell extracts from Absidia corymbifera and Rhizopus oryzae, than voriconazole and fluconazole. Similarly, expression of CYP51 from R. oryzae in Saccharomyces cerevisiae significantly increased resistance to fluconazole and voriconazole but not to posaconazole and itraconazole.


* Corresponding author. Mailing address: Schering-Plough Research Institute, 2015 Galloping Hill Road, 4700, Kenilworth, NJ 07033. Phone: (908) 740-7644. Fax: (908) 740-3918. E-mail: paul.mcnicholas{at}spcorp.com.

{triangledown} Published ahead of print on 11 September 2006.


Antimicrobial Agents and Chemotherapy, November 2006, p. 3917-3919, Vol. 50, No. 11
0066-4804/06/$08.00+0     doi:10.1128/AAC.00747-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Eddine, A. N., von Kries, J. P., Podust, M. V., Warrier, T., Kaufmann, S. H. E., Podust, L. M. (2008). X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14{alpha}-Demethylase (CYP51). J. Biol. Chem. 283: 15152-15159 [Abstract] [Full Text]  
  • Soczo, G., Kardos, G., McNicholas, P. M., Balogh, E., Gergely, L., Varga, I., Kelentey, B., Majoros, L. (2007). Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J Antimicrob Chemother 60: 1004-1009 [Abstract] [Full Text]